A beacon of hope for cancer treatment through daring innovation

GemPharmatech has developed a series of proprietary humanized mouse models targeting immune checkpoint molecules on both BALB/c and C57BL/6 genetic backgrounds. The extracellular regions of the mouse immune checkpoints are replaced with the corresponding human fragments, supporting antibody recognition against human immune checkpoints while ensuring proper intracellular signal transduction through the mouse transmembrane and intracellular portions. These models are suitable for antibody efficacy and safety evaluation including bispecific antibody evaluation for cancer immunotherapy and other applications. We provide comprehensive in vivo R&D testing services to our clients by offering appropriate solutions for disease models and study designs corresponding to their drug’s mechanism of action. We offer 60+ of these mouse models for a myriad of scientific applications. Our goal is to develop 600 humanized models for therapeutic development by the end of 2022.
Immune checkpoint molecules are a type of cell-surface proteins expressed on white blood cells or tumor cells. They act as a gatekeeper of immune responses by either activating or inhibiting signaling pathways upon ligand binding. Immune checkpoint antibodies target these proteins for efficient tumor removal. Breakthroughs in adaptive immune cell therapy (e.g., CAR-T, CAR-NK) and immunotherapies based on checkpoint biology (e.g., PD-1, CTLA-4 antibodies) represent a bright future for cancer treatment and bring hope for better patient care. Despite significant advances in the field, developing humanized immune checkpoint mouse models has emerged as one of the most difficult challenges for preclinical research and drug safety evaluation.

Models are available on dual genetic backgrounds

Single Target

Strain No. Strain Name
T003095 B6-hPD1
T002726 BALB/c-hPD1
T003455 B6-hPDL1
T003260 BALB/c-hPDL1
T003366 B6-hTIGIT
T003365 BALB/c-hTIGIT
T003362 B6-hCTLA4
T003361 BALB/c-hCTLA4
T003360 B6-hCD137
T003359 BALB/c-hCD137
T001550 BALB/c-hCD3E
T009031 BALB/c-hCD3EDG
T003597 B6-hLAG3
T003894 BALB/c-hTIM3
T003585 B6-hBTLA
T004615 B6-hSIRPα
T007666 B6-hCD47
T014646 BALB/c-hCD47
T002140 B6-hOX40
T004363 BALB/c-hOX40
T014695 B6-hCD73
T006214 B6/JGpt-hFCGRT
T014757 BALB/c-hVISTA


Double Target

Strain No. Strain Name
T004022 B6-hPD1/hPDL1
T004025 BALB/c-hPD1/hPDL1
T004024 B6-hPD1/hTIGIT
T004023 BALB/c-hPD1/hTIGIT
T003826 B6-hPD1/hCTLA4
T003720 BALB/c-hPD1/hCTLA4
T004082 B6-hPD1/hCD137
T004005 BALB/c-hPD1/hCD137
T004621 B6-hPD1/hLAG3
T004622 BALB/c-hPD1/hLAG3
T004795 BALB/c-hPD1/hTIM3
T009737 B6-hPD1/hTIM3
T004279 B6-hPD1/hCD28
T006778 B6-hPD1/hCD27
T004081 B6-hPD1/hBTLA
T004138 BALB/c-hPD1/hBTLA
T004061 BALB/c-hPD1/hGITR
T006929 B6-hPD1/hSIRPa
T004666 B6-hPD1/hCD47
T005314 BALB/c-hPD1/hSIRPα
T037264 BALB/c-hCD47/hSIRPα
T005313 BALB/c-hPD1/hCD47
T003804 BALB/c-hPD1/hOX40
T004421 B6-hPD1/hOX40-V2
T003532 B6-hPD1/hOX40
T006213 B6-hPD1/hCSF1R


Multi Target

Strain No. Strain Name
T006873 B6J-hPD1/hPDL1/hTIGIT
T037004 BALB/c-hPD1/hPDL1/hTIGIT
T007058 BALB/c-hPD1/hPDL1/hCTLA4
T007056 BALB/c-hPD1/hPDL1/hCD137
T006876 B6-hPD1/hPDL1/hLAG3
T037005 BALB/c-hPD1/hPDL1/hLAG3
T007059 BALB/c-hPD1/hPDL1/hTIM3
T050194 BALB/c-hPD1/hPDL1/hSIRPα
T009410 B6-hPD1/hPDL1/hCD73
T036652 BALB/c-hPD1/hPDL1/hCD73


Advantages of GemPharmatech’s Humanized Immune Checkpoint Mouse Models:

  • Single, double, and triple knockin models of all known human immune checkpoint targets
  • Better simulation of the clinical side effects of immune checkpoint antibody drugs
  • Better suitability for evaluating combination therapy or comparing different drug candidates
You may also be interested in syngeneic mouse models.
hPD1, hPD-1, PD-1, PD1, pd 1, hpdl1, pdl1, htigit, tigit, hctla4, ctla4, hcd137, cd137, hcd3e, cd3e, hcd3edg, cd3edg, hlag3, lag3, htim3, tim3, hbtla, btla, hsirpa, sirpa, hSIRPα, hcd47, cd47, h0x40, 0x40, ox4o, hcd73, fcgrt, vista, cd28, cd27, btla, gitr, cd47, 0x40-v2, 0x40 v2, csf1r